Design with Value, Deliver with Confidence
Pricing is a critical driver of market access success. But with cost containment pressures rising, achieving the right balance between commercial objectives and payer acceptability is more complex than ever. At Kintiga, we develop pricing strategies that are both ambitious and grounded in data, informed by local HTA body and payer expectations, and aligned with your overall market access goals.
Our capabilities include:
- International reference pricing (IRP) scenario planning
- Willingness-to-pay assessments and analogue analysis
- Price-volume trade-off modelling
- Strategic launch sequence optimisation
- Risk-sharing and managed entry agreement support
Our Services
Whether you are entering one or multiple markets, we help you build and justify a pricing strategy that holds up under payer scrutiny—and delivers long-term value.
Development of product- or product portfolio-related pricing strategies for pharmaceutical, medical device, or digital innovations. Positioning strategies and strategic consulting regarding the launch sequence of pharmaceuticals in the European single market.
- Market and price analysis: Conducting market and price analyses to identify and profile direct and indirect competitors in preparation of a market access strategy and appropriate product positioning. Conducting payer advisory boards.
- Cost-benefit analysis: Creation of structured and target-specific cost-benefit analyses (including Excel modelling) to evaluate and demonstrate the economic benefits and cost-effectiveness of medical products.
- Commercial Flexibility: Management of prices and discounts throughout the entire product life cycle of pharmaceutical, medical device and digital products.
- Price modelling: Creation of pricing models for the preparation of contract negotiations with payers to determine reimbursement amounts for pharmaceuticals. Development of performance-based reimbursement models, risk-sharing, or cap models.
- Complex scenarios: Multiple indication pricing strategies and combination medicines considerations.
We understand the pressure of balancing HTA and payer expectations, patients’ needs, and business goals, partnering with you to ensure your pricing is both sustainable and impactful.
We support with:
- Comprehensive payer negotiation support
- Pricing research and modelling, market landscaping and cost-effectiveness assessments
- Launch sequencing through international reference pricing
- Stakeholder insight gathering
- Payer research
- Performance-based reimbursement and outcomes-based models
- Contract and procurement negotiations with regional health insurers across Europe
- Complex therapies, such as cell and gene therapies and ATMPs
Driving change, delivering results.
Our work speaks for itself. From influencing policy shifts to improving access, explore the measurable results and real-world impact we’ve delivered for our clients and their patients.
Our approach
Holistic, systemic analysis:
We take the external perspective and combine it our client’s internal view through interviews or advisory boards with payers, physicians, and patients, as well as through a comprehensive analysis that evaluates all precedents and possible treatment options. We compare this perspective with your organisation’s perspective and harmonise as a basis for the final determination of the launch price and defining floor price, i.e., the economically viable minimum reimbursement amount.
Contingencies become decisions
Kintiga systematically decodes the various dependencies in the European reference price system and presents them transparently in realistic scenarios. This gives those responsible for pricing complete decision-making confidence .
Across national borders and obstacles
Our experience shows that communicating the specific complexity with a country or regions presents a particular challenge. Kintiga supports coordination with European and international organisations and can conduct primary market research for pricing if needed.
